BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34020808)

  • 1. The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI).
    van de Vlasakker VCJ; Lurvink RJ; Cashin PH; Ceelen W; Deraco M; Goéré D; González-Moreno S; Lehmann K; Li Y; Moran B; Morris DL; Piso P; Quadros CA; Rau B; Somashekhar SP; Sommariva A; van der Speeten K; Spiliotis J; Sugarbaker PH; Teo MCC; Verwaal VJ; Yonemura Y; Glehen O; de Hingh IHJT
    Eur J Surg Oncol; 2021 Nov; 47(11):2888-2892. PubMed ID: 34020808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI).
    Bushati M; Rovers KP; Sommariva A; Sugarbaker PH; Morris DL; Yonemura Y; Quadros CA; Somashekhar SP; Ceelen W; Dubé P; Li Y; Verwaal VJ; Glehen O; Piso P; Spiliotis J; Teo MCC; González-Moreno S; Cashin PH; Lehmann K; Deraco M; Moran B; de Hingh IHJT
    Eur J Surg Oncol; 2018 Dec; 44(12):1942-1948. PubMed ID: 30075978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2022 Peritoneal Surface Oncology Group International Consensus on HIPEC Regimens for Peritoneal Malignancies: Colorectal Cancer.
    Hübner M; van Der Speeten K; Govaerts K; de Hingh I; Villeneuve L; Kusamura S; Glehen O
    Ann Surg Oncol; 2024 Jan; 31(1):567-576. PubMed ID: 37940803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic Nodes of Patient Selection for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Among Colorectal Cancer Patients: A Swiss National Multicenter Survey.
    Steffen T; Putora PM; Hübner M; Gloor B; Lehmann K; Kettelhack C; Adamina M; Peterli R; Schmidt J; Ris F; Glatzer M
    Clin Colorectal Cancer; 2019 Dec; 18(4):e335-e342. PubMed ID: 31371166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitomycin-C versus oxaliplatin during cytoreductive surgery and HIPEC for peritoneal metastases secondary to colorectal carcinoma: a retrospective analysis.
    Spiliotis J; Kalles V; Prodromidou A; Raptis A; Ferfelis M; Christopoulou A; Tsiatas M
    J BUON; 2021; 26(4):1260-1265. PubMed ID: 34564979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term survival after hyperthermic intraperitoneal chemotherapy using mitomycin C or oxaliplatin in colorectal cancer patients with synchronous peritoneal metastases: A nationwide comparative study.
    Bakkers C; van Erning FN; Rovers KP; Nienhuijs SW; Burger JW; Lemmens VE; Aalbers AG; Kok NF; Boerma D; Brandt AR; Hemmer PH; van Grevenstein WM; de Reuver PR; Tanis PJ; Tuynman JB; de Hingh IH
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1902-1907. PubMed ID: 32340819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal Peritoneal Metastases Treated by Perioperative Systemic Chemotherapy and Cytoreductive Surgery With or Without Mitomycin C-Based HIPEC: A Comparative Study Using the Peritoneal Surface Disease Severity Score (PSDSS).
    Baratti D; Kusamura S; Azmi N; Guaglio M; Montenovo M; Deraco M
    Ann Surg Oncol; 2020 Jan; 27(1):98-106. PubMed ID: 31691116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current practice in cytoreductive surgery and HIPEC for metastatic peritoneal disease: Spanish multicentric survey.
    Morales-Soriano R; Esteve-Pérez N; Segura-Sampedro JJ; Cascales-Campos P; Barrios P;
    Eur J Surg Oncol; 2018 Feb; 44(2):228-236. PubMed ID: 29242018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic review of published literature on oxaliplatin and mitomycin C as chemotherapeutic agents for hyperthermic intraperitoneal chemotherapy in patients with peritoneal metastases from colorectal cancer.
    Wisselink DD; Braakhuis LLF; Gallo G; van Grevenstein WMU; van Dieren S; Kok NFM; de Reuver PR; Tanis PJ; de Hingh IHJT
    Crit Rev Oncol Hematol; 2019 Oct; 142():119-129. PubMed ID: 31400583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    Rovers KP; Bakkers C; Nienhuijs SW; Burger JWA; Creemers GM; Thijs AMJ; Brandt-Kerkhof ARM; Madsen EVE; van Meerten E; Tuynman JB; Kusters M; Versteeg KS; Aalbers AGJ; Kok NFM; Buffart TE; Wiezer MJ; Boerma D; Los M; de Reuver PR; Bremers AJA; Verheul HMW; Kruijff S; de Groot DJA; Witkamp AJ; van Grevenstein WMU; Koopman M; Nederend J; Lahaye MJ; Kranenburg O; Fijneman RJA; van 't Erve I; Snaebjornsson P; Hemmer PHJ; Dijkgraaf MGW; Punt CJA; Tanis PJ; de Hingh IHJT;
    JAMA Surg; 2021 Aug; 156(8):710-720. PubMed ID: 34009291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complete cytoreductive surgery is the key to improving survival of colorectal cancer patients with peritoneal metastases: comment on PROPHYLOCHIP and PRODIGE 7].
    An SL; Cai J; Wang H; Li Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):220-224. PubMed ID: 34645165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC.
    Latin American Registry of Peritoneal Diseases – LARPD participants
    Eur J Surg Oncol; 2018 Nov; 44(11):1800-1804. PubMed ID: 30037640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Birgisson H; Enblad M; Artursson S; Ghanipour L; Cashin P; Graf W
    Eur J Surg Oncol; 2020 Dec; 46(12):2283-2291. PubMed ID: 32873455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oxaliplatin-based chemotherapy on chemosensitivity in patients with peritoneal metastasis from colorectal cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: proof-of-concept study.
    Prabhu A; Brandl A; Wakama S; Sako S; Ishibashi H; Mizumoto A; Takao N; Ichinose M; Motoi S; Liu Y; Yonemura Y
    BJS Open; 2021 Mar; 5(2):. PubMed ID: 33839755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road?
    Ceelen W
    Eur J Surg Oncol; 2019 Mar; 45(3):400-402. PubMed ID: 30392745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
    Hulshof EC; Lurvink RJ; Caserta N; de Hingh IHJT; van Wezel T; Böhringer S; Swen JJ; Gelderblom H; Guchelaar HJ; Deenen MJ
    Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1925-1931. PubMed ID: 32354538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoreductive surgery plus hyperthermic intraoperative peritoneal chemotherapy for people with peritoneal metastases from colorectal, ovarian or gastric origin: A systematic review of randomized controlled trials.
    Gurusamy K; Leung J; Vale C; Roberts D; Linden A; Tan XW; Taribagil P; Patel S; Pizzo E; Davidson B; Saunders M; Aziz O; O'Dwyer ST
    World J Surg; 2024 Jun; 48(6):1385-1403. PubMed ID: 38658171
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current practices and barriers to referral for cytoreductive surgery and HIPEC among colorectal surgeons: A binational survey.
    Siddiqui J; Brown K; Zahid A; Young CJ
    Eur J Surg Oncol; 2020 Jan; 46(1):166-172. PubMed ID: 31542240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytoreductive surgery (CRS) with hyperthermic intraoperative peritoneal chemotherapy (HIPEC) versus standard of care (SoC) in people with peritoneal metastases from colorectal, ovarian or gastric origin: protocol for a systematic review and individual participant data (IPD) meta-analyses of effectiveness and cost-effectiveness.
    Gurusamy K; Vale CL; Pizzo E; Bhanot R; Davidson BR; Mould T; Mughal M; Saunders M; Aziz O; O'Dwyer S
    BMJ Open; 2020 May; 10(5):e039314. PubMed ID: 32404398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial.
    Quénet F; Elias D; Roca L; Goéré D; Ghouti L; Pocard M; Facy O; Arvieux C; Lorimier G; Pezet D; Marchal F; Loi V; Meeus P; Juzyna B; de Forges H; Paineau J; Glehen O;
    Lancet Oncol; 2021 Feb; 22(2):256-266. PubMed ID: 33476595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.